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ABSTRACT
Purpose To develop an evidence-based clinical
practice guideline for the prevention of oral
mucositis in children (0–18 years) receiving
treatment for cancer or undergoing
haematopoietic stem cell transplantation (HSCT).
Methods The Mucositis Prevention Guideline
Development Group was interdisciplinary and
included internationally recognised experts in
paediatric mucositis. For the evidence review, we
included randomised controlled trials (RCTs)
conducted in either children or adults evaluating
the following interventions selected according to
prespecified criteria: cryotherapy, low level light
therapy (LLLT) and keratinocyte growth factor
(KGF). We also examined RCTs of any
intervention conducted in children. For all
systematic reviews, we synthesised the
occurrence of severe oral mucositis. The Grades
of Recommendation, Assessment, Development
and Evaluation approach was used to describe
quality of evidence and strength of
recommendations.
Results We suggest cryotherapy or LLLT may be
offered to cooperative children receiving
chemotherapy or HSCT conditioning with
regimens associated with a high rate of
mucositis. We also suggest KGF may be offered
to children receiving HSCT conditioning with
regimens associated with a high rate of severe
mucositis. However, KGF use merits caution as
there is a lack of efficacy and toxicity data in
children, and a lack of long-term follow-up data
in paediatric cancers. No other interventions
were recommended for oral mucositis prevention
in children.
Conclusions All three specific interventions
evaluated in this clinical practice guideline were

associated with a weak recommendation for use.
There may be important organisational and cost
barriers to the adoption of LLLT and KGF.
Considerations for implementation and key
research gaps are highlighted.

INTRODUCTION
Oral and oropharyngeal mucositis are
important and common consequences of
cytotoxic cancer treatment and haematopoietic stem cell transplantation (HSCT)
conditioning in adults and children.1 This
guideline for the prevention of oral and
oropharyngeal mucositis was developed
in order to prevent or reduce the severity
of mucositis in children 0–18 years of age
receiving cytotoxic chemotherapy or
radiotherapy for cancer or undergoing
HSCT. For the purpose of this guideline,
oesophageal mucositis is encompassed by
the terms oral and oropharyngeal mucositis; these conditions will be referred to
as oral mucositis for the remainder of
this guideline for the sake of brevity.
Oral mucositis is a complex phenomenon that involves a wide variety of cells
and tissues of the oral mucosa.2 It may
cause severe mouth and throat pain, and
lead to the inability to eat and drink,
sometimes resulting in hospitalisation
for hydration or parenteral nutrition.
Mucositis also provides a portal of entry
for bacteria residing within the oral
cavity, leading to bacteraemia with mouth
flora such as viridans group streptococci.3
In addition, oral mucositis has become a
major dose-limiting toxicity and, consequently, may limit the ability to deliver
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anticancer therapy.4 Finally, there is growing recognition of the impact of oral mucositis on quality of life
and of its economic burden.5
We have explicitly excluded lower gastrointestinal
mucositis from the scope of this guideline. While oral
hygiene is an important component of clinical care,
we have not addressed its role in the prevention or
reduction of oral mucositis, as good oral care should
be encouraged in all children, including children with
cancer.6 Reduction or modification of subsequent
chemotherapy as an option for secondary oral mucositis prevention is outside the scope of this guideline.
The target users of this guideline are healthcare providers who care for children (0–18 years) who are
receiving chemotherapy and/or radiotherapy for
cancer or undergoing HSCT, and who are at risk of
experiencing oral mucositis. This guideline is aimed
particularly at physicians, nurse practitioners, nurses,
pharmacists and dentists treating paediatric oncology,
and HSCT patients. The overall objective was to
develop an evidence-based clinical practice guideline
for the prevention of oral mucositis in children (0–
18 years) receiving treatment for cancer or undergoing
HSCT.
METHODS
Guideline development panel

The Pediatric Oncology Group of Ontario (POGO)
Mucositis Prevention Guideline Development Group
was formed in March 2014 (see online supplementary
appendix 1). Members were selected with a view to
obtain interdisciplinary representation from internationally recognised experts in paediatric mucositis
and POGO institutions. Panel members completed
conflict of interest forms; no members had important
conflicts. The guideline was editorially independent
from the funding body.
Evidence identification and synthesis

There is a large literature base of studies that evaluate
oral mucositis prevention in single arm and randomised controlled trials (RCTs) among adult and paediatric populations. Biologically, interventions that are
effective in adult populations are likely to have a
similar effect in children. However, differences in efficacy may arise related to changing pharmacokinetics
and pharmacodynamics, age-related variance in the
distribution of receptors for targeted interventions
and lack of patient cooperation for some interventions. Specific interventions may have less utility in
children if there is limited use of an antineoplastic
agent in children when the mechanism of protective
activity is agent specific. Toxicities of therapy may
also be different and interference with anticancer
activity may differ by underlying tumour type.
Paediatric studies are also critical to determine dosing
recommendations. Consequently, we decided to
8

evaluate the adult and paediatric literature with an
emphasis on the appraisal of paediatric studies.
In order to limit the scope of the adult and paediatric review, we took a pragmatic approach that
builds on work conducted by a recent Cochrane
Collaboration systematic review,7 and The Mucositis
Study Group of the Multinational Association of
Supportive Care in Cancer and International Society
of Oral Oncology (MASCC/ISOO).8–17 More specifically, because our health question was to identify
prophylactic interventions that are effective at preventing or reducing the severity of oral mucositis, we
chose to systematically review interventions that
were recommended or suggested in any population
by MASCC/ISOO for the prevention of oral mucositis and that showed evidence of benefit in the
Cochrane Collaboration systematic review. These
interventions were cryotherapy, low level light
therapy (LLLT) and keratinocyte growth factor
(KGF). Since the best way to evaluate the efficacy of
an intervention is through conduct of RCTs, we evaluated RCTs of these agents in any age group and
assessed if the effect appeared to differ by adult or
paediatric population. We did not conduct systematic
reviews of agents that the MASCC/ISOO guideline
recommended against using.
We also conducted additional reviews restricted to
paediatric patients. Because of the potential risk of
harm with KGF in children, we undertook a systematic review of any primary study type of KGF use in
paediatric cancer or HSCT. Finally, in order to better
understand the full scope of the evidence base for
mucositis prevention in children, we conducted a systematic review of all RCTs of any intervention to
prevent oral mucositis in paediatric patients. If an
agent other than cryotherapy, LLLT or KGF appeared
promising in children, we had planned to conduct a
combined adult and paediatric review of that agent.
The search strategies, selection criteria, approach to
appraisal and specific search details can be found in
online supplementary appendix 2.
For all systematic reviews, we synthesised the occurrence of severe oral mucositis when at least three
studies reported on this outcome for a specific intervention. Severe oral mucositis was defined as WHO,
National Cancer Institute—Common Terminology
Criteria for Adverse Events (NCI-CTCAE) V.2.0 or
Radiation Therapy Oncology Group (RTOG) scale
score of 3 or 4. All these scores use a five-point scale
ranging from 0 to 4 in which scores of 3 and 4 represent the worst mucositis. The NCI-CTCAE V.3.0 scale
ranges from 1 to 5 in which 5 is fatal mucositis.
NCI-CTCAE V.3.0 scores of 3–5 were considered
severe. All syntheses used the risk ratio (RR) as the
effect measure where ratios less than 1 suggest that
the intervention is better than placebo or no therapy.
The 95% CI was also described. As we anticipated
heterogeneity across studies, a random effects model
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was used for all analyses. Analyses were conducted
using Review Manager (RevMan, V.5.2, Copenhagen:
The Nordic Cochrane Centre, The Cochrane
Collaboration, 2011).
Decision-making process for formulation of the
recommendations

We identified outcomes most important for this guideline. Outcomes of critical importance were severe oral
mucositis, mucositis of any severity, pain and adverse
events associated with the intervention. Outcomes of
lower importance included receipt of opioid analgesia,
enteral or parenteral nutrition, infection outcomes
and fever, since these outcomes are subject to confounding and institutional variation.
We used the Grades of Recommendation, Assessment,
Development and Evaluation (GRADE) approach to
describe quality of evidence and strength of recommendations.18 19 Quality of evidence was evaluated in terms
of risk of bias (methodological limitations), imprecision
of estimates, inconsistency of results between studies
and indirectness (lack of applicability to the target population). In this guideline, indirectness primarily occurred
when the data were not paediatric specific. A strong recommendation was made when benefits clearly outweighed the risks and burdens or vice versa. In contrast,
a weak recommendation was made when benefits and
risks or burdens were closely matched, or when there
was considerable uncertainty about the magnitude of
the benefits and risks. Each recommendation was carefully deliberated by the panel. Decisions were taken
through panel discussions and any differences in
opinion were resolved by consensus.

External review, consultative process and plans for
updates

The draft guideline was distributed to 12 external
experts in adult and paediatric mucositis. Specific
recommendations were reviewed by the panel and the
guideline was revised accordingly. The guideline
development process took 6 months from constitution
of the panel to guideline completion. This guideline
will be reviewed every 5 years or earlier if important
new information becomes available.
RESULTS
Online supplementary appendix 3 outlines the results
of the search strategies and flow charts of study identification, selection and reasons for exclusion. Table 1
presents the summary of recommendations, strength
of recommendations, level of evidence and remarks.
Health question

What prophylactic interventions are effective at preventing or reducing the severity of oral mucositis in
children (0–18 years) receiving treatment for cancer
or undergoing HSCT
Recommendation 1.1: We suggest that cryotherapy
may be offered to cooperative children receiving
chemotherapy or HSCT conditioning with regimens
associated with a high rate of mucositis.
Remarks: This recommendation places high value
on the possible reduction in mucositis with an intervention with a low risk of harm. It is a weak recommendation because of the lack of paediatric-specific
evidence, because the majority of studies that demonstrated the benefit of cryotherapy were conducted

Table 1 Summary of recommendations for the prevention of oral mucositis in paediatric patients receiving treatment for cancer or
undergoing haematopoietic stem cell transplantation

Health question and recommendations

Strength of
recommendation
Level of evidence

What prophylactic interventions are effective at preventing or reducing the severity of oral and oropharyngeal mucositis in children (0–18 years) receiving
treatment for cancer or undergoing haematopoietic stem cell transplantation (HSCT)?
Recommendation 1.1: We suggest that cryotherapy may be offered to cooperative children receiving chemotherapy or
Weak recommendation
HSCT conditioning with regimens associated with a high rate of mucositis
Moderate-quality evidence
Remarks: This recommendation places high value on the possible reduction in mucositis with an intervention with a low
risk of harm. It is a weak recommendation because of the lack of paediatric-specific evidence, because the majority of
studies that demonstrated the benefit of cryotherapy were conducted using chemotherapy regimens not commonly given to
children and because of the methodological limitations of the conducted trials. Regimens appropriate for cryotherapy are
restricted to agents with a short infusion time and a short half-life
Weak recommendation
Recommendation 1.2: We suggest that low-level light therapy may be offered to cooperative children receiving
High-quality evidence
chemotherapy or HSCT conditioning with regimens associated with a high rate of mucositis
Remarks: This recommendation places high value on the possible reduction in mucositis with an intervention with a low
risk of harm. It is a weak recommendation because this strategy requires specialised equipment and expertise and it is
unknown whether it is feasible to deliver this therapy modality in routine clinical practice, particularly in a paediatric
population. The ideal treatment parameters and cost-effectiveness of this approach are unknown
Weak recommendation
Recommendation 1.3: We suggest that keratinocyte growth factor (KGF) may be offered to children receiving HSCT
High-quality evidence
conditioning with regimens associated with a high rate of severe mucositis
Remarks: This recommendation places high value on the evidence of efficacy of KGF in adult populations. It is a weak
recommendation because of the lack of efficacy and toxicity data in children, a theoretical concern that young children may
be at increased risk of adverse effects related to mucosal thickening and the lack of long-term follow-up data in paediatric
cancers
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using chemotherapy regimens not commonly given to
children and because of the methodological limitations of the conducted trials. Regimens appropriate
for cryotherapy are restricted to agents with a short
infusion time and short half-life.
Oral cryotherapy involves placing ice cubes or ice
chips in the mouth and continually replenishing fresh
ice during the period of cytotoxic treatment (typically
30–60 min). It is an attractive intervention because of
its low cost and universal access. In reviewing the
evidence tables (see online supplementary appendices
4–6), there have been 14 RCTs conducted of cryotherapy in which 1301 patients have been randomised. In
13 studies, cryotherapy was given during chemotherapy administration and in 1 study, it was given before
and after localised radiotherapy to the head and neck.
Of the 14 studies, 12 reported a benefit of cryotherapy. Figure 1 illustrates that cryotherapy significantly
reduced severe oral mucositis (RR 0.46, 95% CI 0.30
to 0.71; p=0.0005) among the eight studies reporting
this outcome.
In spite of the many RCTs available, the quality of
evidence supporting this recommendation was only
moderate due to indirectness and limitations in study
design. Only one study included children, and the
youngest child was 8 years of age.20 This study
included adults and children undergoing allogeneic
HSCT, and cryotherapy was administered with
low-dose methotrexate for graft-versus-host disease
(GVHD) prophylaxis. Notably, this study was one of
only two studies that failed to show a benefit of cryotherapy. Likely, the conditioning regimen contributed
much more to the risk of mucositis than did low-dose
methotrexate given for GVHD prophylaxis; thus, this
study is difficult to interpret. In addition, the most
common regimen used in the studies of cryotherapy
was 5-fluorouracil (8/14 studies); this agent is rarely
used in children. Indirectness is also a concern as
there is likely to be an age at which children cannot

or will not comply with cryotherapy during chemotherapy administration.
Limitations in study design are also a concern.
Online supplementary appendix 5 illustrates that three
of the studies were quasi-RCTs. Adequate sequence
generation was only present for two studies and it was
inadequate in three. None of the 14 RCTs adequately
concealed allocation, a major methodological limitation, as lack of allocation concealment has been associated with exaggerated treatment effects.21 Finally,
only two studies used blinded outcome assessors. The
low quality of the RCTs evaluating the efficacy of
cryotherapy for mucositis prevention raises concerns
about the possibility of bias.
Cryotherapy is only feasible if chemotherapy is
administered as a short infusion and has a short halflife. The chemotherapeutic agents used in the studies
of cryotherapy were 5-fluorouracil (8 studies), melphalan as conditioning for HSCT (2 studies), a variety
of conditioning regimens for autologous and allogeneic HSCT (1 study), and etoposide, cisplatin,
mitomycin-C and vinblastine (1 study). It would be
reasonable to use cryotherapy for paediatric patients
receiving short infusions of these chemotherapeutic
agents. In addition, since the biological mechanism
underlying the effect of cryotherapy is likely related
to reduced distribution of the cytotoxic agent to the
oral mucosa due to vasoconstriction, it may also be
reasonable to use cryotherapy for other regimens associated with a higher risk of mucositis as long as the
regimen is given over a short period of time such as
30 min, and the agent has a short half-life. Flavoured
ice popsicles, ice slushy drinks or ‘freezies’ are likely
to be more acceptable to children than plain ice.
There are two safety considerations with cryotherapy. First, if ice chips are to be used, they may be a
choking hazard in very young children, although children who are old enough to comply with cryotherapy
are unlikely to be at risk for choking. Second,

Figure 1 Cryotherapy versus no cryotherapy for the reduction of severe oral mucositis in patients receiving treatment for cancer or
undergoing haematopoietic stem cell transplantation. Forest plot of incidence of severe (grade 3 or 4) mucositis in adults and
children randomised to cryotherapy, versus no cryotherapy in patients with cancer and those receiving haematopoietic stem cell
transplantation. Squares to the left of the vertical line indicate that the intervention reduces mucositis. Horizontal lines through the
squares represent CIs. The size of the squares reflects each study’s relative weight, and the diamond represents the aggregate risk
ratio and 95% CI.
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vasoconstriction of the oral tissues may influence local
anticancer activity, although this issue has not been
noted in the adult studies.
Recommendation 1.2: We suggest that LLLT may be
offered to cooperative children receiving chemotherapy or HSCT conditioning with regimens associated
with a high rate of mucositis.
Remarks: This recommendation places high value
on the possible reduction in mucositis with an intervention with a low risk of harm. It is a weak recommendation because this strategy requires specialised
equipment and expertise, and it is unknown whether
it is feasible to deliver this therapy modality in routine
clinical practice, particularly in a paediatric population. The ideal treatment parameters and costeffectiveness of this approach are unknown.
LLLT is based on the physiological effects of lowenergy light without thermal generation. The main
effects of phototherapy are anti-inflammatory, influence on wound healing and analgesic. While the
precise mechanism of action of LLLT in preventing
oral mucositis is not fully understood, a number of biological effects have been well characterised at the
molecular, cellular and tissue-based levels.22 It is typically administered intraorally, although there is some
experience with external application. In the systematic
review by Oberoi et al,23 18 prophylactic LLLT studies
were identified; online supplementary appendix 7
summarises the type of laser, wavelength, energy and
laser schedule. LLLT significantly reduced the incidence of severe mucositis (RR 0.37, 95% CI 0.20 to
0.67; p=0.001). LLLT also reduced the incidence of
severe pain (RR 0.26, 95% CI 0.18 to 0.37;
p<0.0001). Two studies included children and there
was no difference in the effect of LLLT by age ( p for
interaction=0.90). One study included adults and children receiving autologous or allogeneic HSCT24 while
the second study included children receiving chemotherapy or autologous HSCT.25 There was no difference in the effect of LLLT by underlying condition
( patients with head and neck cancer receiving radiotherapy or chemoradiotherapy versus patients receiving
chemotherapy or HSCT; p for interaction=0.85).
The review identified a significant interaction by
allocation concealment, with the effect of LLLT to
prevent severe mucositis being RR 0.61 (95% CI 0.30
to 1.25) in studies with adequate concealment and RR
0.16 (95% CI 0.07 to 0.41) for studies with unclear
or inadequate concealment ( p for interaction=0.03).
There was also evidence of publication bias with four
outlying studies in the funnel plot. When the ‘trim
and fill’ technique26 was used to account for publication bias, the effect of LLLT remained significant (RR
0.51, 95% CI 0.29 to 0.90; p=0.0197).
In summary, LLLT is effective in reducing severe
mucositis in patients receiving treatment for cancer
and undergoing HSCT, although methodological concerns and potential publication bias may mean that

the treatment effects observed in these trials are
exaggerated.
Recommendation 1.3: We suggest that KGF may be
offered to children receiving HSCT conditioning with
regimens associated with a high rate of severe
mucositis.
Remarks: This recommendation places high value
on the evidence of efficacy of KGF in adult populations. It is a weak recommendation because of the
lack of efficacy and toxicity data in children, a theoretical concern that young children may be at increased
risk of adverse effects related to mucosal thickening
and the lack of long-term follow-up data in paediatric
cancers.
KGF is an epithelial growth factor; it is a 28 kD,
heparin-binding member of the family of fibroblast
growth factors. The most commonly studied KGF is
palifermin, a recombinant human KGF. It is contraindicated in patients with known hypersensitivity to
Escherichia coli derived proteins. Online supplementary appendices 8–10 describe the 11 RCTs conducted
of KGF; they included 1470 randomised patients. Ten
studies evaluated palifermin while one study evaluated
repifermin (no longer available). Use of KGF was evaluated in the context of HSCT conditioning (5
studies); chemoradiotherapy for head and neck cancer
(3 studies); and chemotherapy alone (3 studies). Of
the 11 studies, 9 reported a benefit of KGF.
Figure 2 illustrates that KGF significantly reduced
severe oral mucositis (RR 0.81, 95% CI 0.67 to 0.97;
p=0.02) in the eight studies reporting this outcome.
Primary toxicities were related to the pharmacological
properties of the agent with thickening of the oral
mucosa and altered taste sensation. The quality of
these studies was high and all studies were placebo
controlled. All 11 trials were sponsored by a pharmaceutical company. Only one study included children,
and it evaluated KGF for the prevention of GVHD
following allogeneic HSCT in a mixed adult and
paediatric sample.27 Mucositis severity was evaluated
as a secondary outcome and a significant reduction in
the mean severity of oral mucositis with KGF compared with placebo was observed (WHO 2.3 vs 2.8;
p=0.01). In a long-term follow-up of this study, no
difference in invasive fungal infection, chronic
GVHD, or overall survival between the KGF and
placebo cohorts was evident at 2 years.28 However,
relapse rates were not described, few patients had
solid tumours (number not specified) and outcomes
were not specifically reported for paediatric patients.
In the systematic review of any primary study type
of KGF in paediatric populations, four nonrandomised studies were identified, all in the HSCT
setting. First, a phase 1 allogeneic HSCT study evaluated doses of 40, 60 and 90 μg/kg/day given 3 days
before conditioning and 3 days after stem cell infusion
in children 2–18 years of age.29 Six children received
90 mg/kg/day; no dose-limiting toxicities were
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Figure 2 Keratinocyte growth factor (KGF) versus no KGF for the reduction of severe oral mucositis in patients receiving treatment
for cancer or undergoing haematopoietic stem cell transplantation. Forest plot of incidence of severe (grade 3 or 4) mucositis in
adults and children randomised to KGF versus no KGF in patients with cancer and those receiving haematopoietic stem cell
transplantation. Squares to the left of the vertical line indicate that the intervention reduces mucositis. Horizontal lines through the
squares represent CIs. The size of the squares reflects each study’s relative weight, and the diamond represents the aggregate risk
ratio and 95% CI.

observed. Of the 12 patients enrolled, grade 2 or
lower skin rash was observed in 67% and 25% experienced mucositis. Second, an allogeneic HSCT study
evaluated 20 children with acute lymphoblastic leucaemia30 who were 7–16 years of age. Participants
received KGF 60 mg/kg/day for 3 days before and
3 days after myeloablative therapy. Grade 2 or higher
oral mucositis was observed in 60% of KGF-treated
participants compared with 86% of historical control
patients ( p=0.032). Toxicities of KGF were skin rash
(60%), skin erythema (60%), altered taste (10%) and
severe pain in the tongue, buccal mucosa and palate
(10%). Third, an autologous HSCT study included 25
children treated with KGF 60 mg/kg/day for 3 days
before conditioning and 3 days following the last dose
of chemotherapy.31 Severe mucositis occurred in 20%
of KGF-treated patients versus 42% of historical
control patients ( p=0.072). Toxicities of KGF were
not described. Finally, a case report described a
19-year-old patient who received KGF 60 mg/kg/day
for 3 days before and after allogeneic HSCT. He
developed transient non-severe hyperplastic gingivitis
with a concomitant papulopustular skin rash.32
We made a weak recommendation that KGF may be
considered for children undergoing HSCT if the benefits of mucositis prevention outweigh the risks and
costs. If used, KGF should be administered at a dose
of 60–90 mg/kg/day for 3 days prior to conditioning
and 3 days following stem cell infusion.
Other interventions as prophylaxis for oral mucositis

There were 21 paediatric RCTs of interventions to
reduce oral mucositis identified by the search strategy
(see online supplementary appendices 11–13). The
most common intervention evaluated was growth
factors, more specifically subcutaneous or intravenous
granulocyte colony-stimulating factor (GCSF), granulocyte macrophage colony-stimulating factor and
pegfilgrastim in seven studies. In all of these studies,
12

mucositis was a secondary end point. In the four
studies that compared GCSF with no therapy,33–35
one showed a reduction in grade 2–4 NCI-CTCAE
mucositis (2% vs 6%; p=0.002),33 two showed no
decrease in mucositis34 36 and the fourth study
showed inconsistent results depending on the specific
chemotherapy cycle evaluated.35
Other growth factors, glutamine and Traumeel S,
were not consistently effective in reducing mucositis
in paediatric patients in more than one study. Single
studies of topical vitamin E,37 transforming growth
factor-β2-enriched feeding,38 chewing gum,39 chlorhexidine gluconate,40 sucralfate41 and a preventive
oral disease protocol42 were not effective in reducing
mucositis. Given that our focus was on the identification of effective interventions to prevent or reduce
mucositis, we did not make strong or weak recommendations against the use of any of these agents.
Recommendations against the use of an agent would
require adult and paediatric systematic reviews and
the development of specific criteria on which to make
such a recommendation. However, the identification
of ineffective interventions is an important area for
future research and is identified as a research gap.

DISCUSSION
Considerations for implementation

Clinical assessment for the presence and severity of
oral mucositis should be a component of routine care
for children receiving treatment for cancer and undergoing HSCT. Validated screening and assessment tools
are important. A screening tool that includes mucositis
has been developed but has not yet been validated.43 44
Validated mucositis assessment tools in paediatric
patients include the Children’s International Mucositis
Evaluation Scale (ChIMES),45 the Oral Assessment
Guide,46 the Oral Mucositis Assessment Scale47 and
the Oral Mucositis Daily Questionnaire.48
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In this guideline, we identified three interventions
that may be appropriate for mucositis prevention in
children. Figure 3 illustrates an algorithm for strategy
implementation consideration. All three specific interventions (cryotherapy, LLLT and KGF) evaluated in
this clinical practice guideline were associated with a
weak recommendation for use. Since all systematic
reviews compared the intervention against placebo or
no therapy, it may be helpful to compare the RRs to
gain insight into prioritisation. The RR against
placebo or no therapy for LLLT, cryotherapy and KGF
were 0.37, 0.46 and 0.81, respectively. In evaluating
all three interventions, KGF is an intervention associated with high costs and a potential for harm. In
contrast, cryotherapy is associated with very few costs
and little risk of harm. On balance, if all three interventions are available, and clinically relevant, cryotherapy or LLLT should likely be prioritised for
implementation whereas KGF should be used carefully in individual patients after weighing risks and
benefits. There may also be important organisational

and cost barriers to the adoption of LLLT since it
requires specialised equipment and training for those
who will administer therapy.
Dissemination of this guideline will be an important
step in effective knowledge translation. We plan to
disseminate this guideline through peer-reviewed publication, presentation at conferences and through
paediatric oncology and dental organisations.
Research gaps

Research gaps are highlighted in box 1 and include
identification of chemotherapeutic agents appropriate
for cryotherapy. Important research gaps related to
LLLT include better mechanistic information on how
the modality could be effective, determination of ideal
treatment parameters and comprehensive long-term
adverse-effect evaluation, since enhanced bone growth
has been reported in preclinical studies.49 50 For KGF,
research is needed to identify the optimal KGF dose
and its short-term and long-term toxicities in paediatric patients. Data related to compliance and cost-

Figure 3 Suggested implementation approach for the prevention of oral mucositis guideline recommendations (HSCT,
haematopoietic stem cell transplantation; KGF, keratinocyte growth factor, LLLT, low level light therapy).
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Box 1

Key research gaps

Key Research Gaps
▸ The epidemiology of mucositis is poorly understood
in children. Consensus-based approaches should be
used to define what cumulative incidence of mucositis constitutes ‘high risk’. Observational studies are
required to describe the proportion of children receiving specific chemotherapeutic agents and regimens
expected to experience any mucositis and severe
mucositis
▸ Development of risk stratification schemas for paediatric mucositis
▸ Identification of paediatric anticancer treatment protocols appropriate for cryotherapy
▸ Determination of mechanistic information on mode
of action, ideal treatment parameters and comprehensive long-term adverse-effect evaluation for low
level light therapy
▸ Identification of the optimal paediatric dose of keratinocyte growth factor, and its short and long-term
toxicities in paediatric patients with cancer
▸ Cost-effectiveness analysis of different approaches to
mucositis prevention
▸ Evaluation of the feasibility of each of the recommended interventions to prevent mucositis in clinical
practice
▸ Identification of new effective prophylactic strategies
to prevent mucositis in paediatric patients, particularly for infants and very young children
▸ Identification of ineffective interventions to prevent
mucositis in children
effectiveness are needed for these strategies. More
paediatric evidence is required to evaluate existing
and new interventions to prevent or reduce the severity of mucositis particularly since some children at risk
for mucositis, especially infants and very young children, will not be eligible for any of the interventions
identified in this guideline.
Another important gap is the identification of ineffective interventions to prevent mucositis in children.
In randomised trials, equivalence trials require larger
sample sizes than superiority trials because the
minimal clinically important difference (in superiority
trials) is larger than the margin of clinical equivalence.
In synthesising trial results, it is unclear how much
information is required before concluding equivalence
in efficacy outcomes. Similarly, it is unclear how much
information demonstrating lack of benefit is required
before panels can recommend against use of an agent
for interventions without meaningful harms or costs.
Finally, how panels should weigh indirect adult evidence in making paediatric recommendations against
use of an intervention is another question. Among
these research gaps, research priorities that should be
addressed early include the identification of paediatric
14

anticancer treatment protocols appropriate for cryotherapy, feasibility of cryotherapy and LLLT in clinical
practice, and child preferences for these strategies.
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